RxDoctor Payments Data

Magued Fadly, MD

Pain Medicine · Woodland Hills, CANPI 1194774034

Payments from drug & device makers

$4,660in general payments, 2019–2025

Across 177 payments — averaging $26.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Collegium Pharmaceutical, Inc.$699
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$528
  • Biohaven Pharmaceuticals, Inc.$240
  • Nevro Corp.$164
  • Arbor Pharmaceuticals, Inc.$132
  • plus $869 from 17 others

What the payments were for

  • Food & beverage$4,660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,660 in reported general payments places this provider in the 65th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$312,336
Medicare patients
146
Services billed
1,557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide14$32,907
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen205$4,196
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen54$1,532
Pregabalin63$1,351
Morphine Sulfate ErMorphine Sulfate23$893
Methadone Hcl57$859
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl17$807
Baclofen104$769
Zolpidem Tartrate55$534
Sumatriptan Succinate36$374
Diclofenac Sodium14$354
EndocetOxycodone Hcl/Acetaminophen11$319
Carisoprodol52$289
Diazepam23$237
Gabapentin28$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$528$32,90714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 840 pain medicine providers in California.

Other pain medicine in Woodland Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →